Introduction
Development of KRAS-degrader drugs against cancer
Features / strengths
KRAS PROTAC lead drugs have been developed with inhibitory effect in cells expressing KRAS G12C, G12D, G12V and observed significant protein degradation and >60% tumor in xenograft animal model of KRASG12V non-small cell lung cancer NCI-H441 Inhibition rate.
Specification in detail
Development of KRAS-degrader drugs against cancer
Development of KRAS-degrader drugs against cancer
